Resaphene Suisse AG
8/13/18: "The results of user observation encourage us to conduct a double-blind study in the next step," says Anke Rauterkus, CEO of Resaphene Suisse AG. "The key to the success of the therapy is the combination of warmth and frequency-filtered music. Meanwhile, the prototype for the third series of tinniwell has been developed. The new generation of devices is considerably smaller and will have interfaces to smartphones and other devices in the future."